Navocaftor by Sionna Therapeutics for Cystic Fibrosis: Likelihood of Approval

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Voxzogo given green-light to treat children under five by US FDA –

At present Voxzogo is currently marketed in the European Union in children with achondroplasia who are 2 years of age and older with open growth

October 23, 2023

Does the risk of getting long Covid increase each time you get reinfected?

More than three years into the coronavirus pandemic, fewer and fewer people are experiencing their first Covid-19 infections. But as cases climb, those who’ve had

September 20, 2023

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study – Psychedelic Alpha

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical

August 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.